pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Peptide Therapeutic · news · pharmadog
← back to Peptide Therapeutic
News · Peptide Therapeutic
135
stories
4h
STAT+: Are stem cells the next peptides? These advocates think RFK Jr. could make it happen
stat
9h
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
biospace
2d
Foghorn cuts 40% of workforce
biospace
5d
BioNTech to close German manufacturing plants after failing to find buyers
biospace
5d
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
5d
Roche cuts muscle-sparing obesity drug after mid-stage disappointment
biospace
6d
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
7d
CDER director, expert discuss scientific, legal challenges to bringing generic GLP-1s to market
raps
10d
Novo inks $1.3B Nanexa deal to unlock long-acting obesity injectables
fiercebiotech
12d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
12d
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
13d
Roche reports Phase 2 enicepatide data in overweight or obese patients with diabetes
endpoints
14d
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
14d
Skeptical about modern medicine? I know the feeling — and want to listen
stat
17d
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
17d
Novo partners with Orbis, deepening investment in oral peptide drugs
biopharma dive
17d
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
18d
Novartis halts TREM2 targeting ALS program in 4th trial stumble in a month
biospace
19d
Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech
fiercebiotech
19d
Centric Compounding recalls three injectables over contamination
endpoints
21d
Axoltis misses the mark in phase 2 ALS study, but will persevere with the synthetic peptide
fiercebiotech
21d
Cyclic peptides open new drug frontiers, if manufacturing can keep up
biospace
21d
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
23d
Samsung Biologics inks $262M manufacturing deal with European pharma company
biospace
27d
4 CDMOs to consider when outsourcing manufacturing
biospace
Sep 4, 26
STAT+: FDA takes another look at botanical drugs
stat
Sep 1, 26
Paxlovid did not help long Covid, study finds
stat
Aug 31, 26
New guidelines on migraine prevention reflect increasing options for patients
stat
Aug 31, 26
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
biospace
Aug 31, 26
Takeda, Protagonist score broad FDA nod in rare blood cancer, setting up $2B opportunity
biospace
← prev
page 1 of 5
next →
